Cellect Biotechnology Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Cellect Biotechnology Ltd., a foreign private issuer based in Kfar Saba, Israel, for the month of March 2017. The filing date is March 2, 2017. The report consists solely of a press release announcing a corporate governance update.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report regarding a board appointment and does not contain financial statements or performance data.
Material Changes
The material change disclosed in this filing is the appointment of Michael Berelowitz to the Board of Directors of the Registrant. No financial or operational changes were reported.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on financial performance, risks, contingencies, or unusual items. The press release is incorporated by reference into the registration statement on Form S-8 (Registration No. 333-214817).
Key Facts for Investors to Verify
- Confirmation of Michael Berelowitz's appointment to the Board of Directors.
- Review of the full press release attached as Exhibit 99.1 for details on the new director's background.
- Verification of the incorporation of this announcement into the Form S-8 registration statement.